An innovative medecine for treating herpes labialis

About 1 in 10 people suffer from recurring herpes labialis1 in France. Patients have an average of 3,4 episodes each year, which significantly affect their personal and social life2.

Vectans Pharma launches a therapeutic innovation in France for treating recurrences of herpes labialis in immunocompetent adults who experience frequent outbreaks of herpes. This is the very first treatment that allows a single-dose administration of 50 mg of acyclovir for each herpes labialis episode, now available in pharmacy.

In order to insure a successful launch, Vectans Pharma notably relies on a dedicated team in charge of promoting the product.
Thus, dermatologists, general practicioners and pharmacists can discover this new therapeutic treatment in herpes labialis.

1) Lara El Hayderi and Arjen F. Nikkels. Infections par les virus herpès simplex 1 et 2, In Dermatologie infectieuse, edited by Mourad Mokni, Nicolas Dupin and Pascal del Giuduce, Elsevier Masson, Paris, 2014, Pages 7-16, ISBN 9782294732843,
2) Dreno B, Malkin J-E, Saiag P. Understanding recurrent herpes labialis management and impact on patients’ quality of life: the HERPESCOPE study. Eur J Dermatol 2013; 23(4): 491-9.


Dr Stefan Lempereur appointed as Chief Medical Officer

Vectans Pharma announces the appointment of Dr Stefan Lempereur as its new Chief Medical Officer, effective from March 1st 2018.

“I am delighted to accept the position Chief Medical Officer of Vectans Pharma which aims to play an important role in the development and dissemination of scientific knowledge in the domain of oral mucosa pathologies.”

As Chief Medical Officer, Dr Stefan Lempereur is a member of the Executive Committee at Vectans Pharma.

He is Belgian by nationality, Medical Doctor by training, holding his degree from Liège University, Belgium.

Stefan Lempereur has particularly strong background in Medical Affairs with more than 25 years of experience in the pharma business, mainly with Ipsen and HRA pharma at national and international levels. His areas of expertise are pituitary endocrinology, endocrinological oncology and botulinum toxins.

230 Bureaux de la colline
92213 Saint-Cloud